(secondQuint)A Phase II Study of the FIL on Elderly Frail Patients With DLBCL.

 This is a prospective, multicenter, single arm, phase II trial in elderly patients ( 70 years) affected by DLBCL defined as frail according to CGA and previously untreated.

 The primary endpoint is to evaluate the efficacy of the R2 (Revlimid+Rituximab) combination in first line DLBCL patients not candidate for the standard R-CHOP (or R-CHOP like) treatments due to the frail status.

.

 A Phase II Study of the FIL on Elderly Frail Patients With DLBCL@highlight

A phase II study to evaluate the combination of Lenalidomide and Rituximab as front line therapy for the treatment of elderly frail patients evaluated in CGA with Diffuse Large B-cells non-Hodgkin Lymphoma.

